Adult Congenital Heart Disease and SGLT2 Inhibitors Registry
This international registry is looking at how a type of medication called SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors) is currently being used in adults with congenital heart disease (heart problems present from birth). The study wants to understand how these drugs are prescribed, if they are safe and well-tolerated, and if they help with heart failure symptoms. You may be able to join if you are an adult (18 years or older) with a congenital heart defect and have already started taking an SGLT2 inhibitor. The main goal is to see how these medications are being prescribed at the beginning of the study.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment. It aims to include 400 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
At a glance
Conditions
Where it's being run
11 sites across 8 statesStudy leadership
- Anastasia D. Egorova, MD PhD · PRINCIPAL_INVESTIGATOR · Leiden University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Prescription patternsBaseline information.
The primary outcome of this registry is an overview of the prescription patterns of SGLT2i in the ACHD population.